Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 80/100

Failure Rate

66.7%

2 terminated/withdrawn out of 3 trials

Success Rate

33.3%

-53.2% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

100%

1 of 1 completed trials have results

Key Signals

1 with results

Enrollment Performance

Analytics

Phase 1
2(66.7%)
Phase 2
1(33.3%)
3Total
Phase 1(2)
Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (3)

Showing 3 of 3 trials
NCT03001414Phase 2Terminated

Study of Angiogenic Cell Therapy for Progressive Pulmonary Hypertension

Role: lead

NCT04961658Phase 1Terminated

Advanced Mesenchymal Enhanced Cell THerapY for SepTic Patients

Role: lead

NCT00469027Phase 1Completed

Pulmonary Hypertension: Assessment of Cell Therapy

Role: lead

All 3 trials loaded